Your browser doesn't support javascript.
loading
Biodistribution and toxicology evaluation of a recombinant measles Schwarz-based Lassa vaccine in cynomolgus macaques.
Schrauf, Sabrina; Tomberger, Yvonne; Nambulli, Sham; Duprex, W Paul; Tschismarov, Roland; Tauber, Erich; Ramsauer, Katrin.
Affiliation
  • Schrauf S; Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.
  • Tomberger Y; Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.
  • Nambulli S; Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Duprex WP; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Tschismarov R; Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Tauber E; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Ramsauer K; Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.
J Appl Toxicol ; 43(5): 719-733, 2023 05.
Article in En | MEDLINE | ID: mdl-36480160
MV-LASV is an investigational measles Schwarz-based vaccine for the prevention of Lassa fever. A repeated-dose toxicity study in cynomolgus macaques was performed to assess the biodistribution and local and systemic toxicological effects. Monkeys received three immunizations of MV-LASV or saline intramuscularly with a 2-week interval. An increase in anti-measles antibodies confirmed the reaction of the immune system to the vaccine backbone. Clinical observations, body weight, body temperature, local tolerance, electrocardiogram parameters, various clinical pathology parameters (hematology, coagulation urinalysis, serum chemistry, and C-reactive protein) were monitored. Gross pathology and histopathology of various tissues were evaluated. MV-LASV induced a mild increase in fibrinogen and C-reactive protein concentrations. This coincided with microscopic inflammation at the injection sites which partially or fully resolved following a 3-week recovery period. Viral RNA was found in secondary lymphoid organs and injection sites and gall bladder. No viral shedding to the environment was observed. Overall, the vaccine was locally and systemically well tolerated, supporting a first-in-human study.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Measles Vaccine / Lassa Fever Limits: Animals / Humans Language: En Journal: J Appl Toxicol Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Measles Vaccine / Lassa Fever Limits: Animals / Humans Language: En Journal: J Appl Toxicol Year: 2023 Type: Article Affiliation country: United States